,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2018', 'fs': 'Sep 2018', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZFTUA2'}, 'Id': 'a0P2P000006hZFTUA2', 'Event_Date__c': '2018-09-14', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Sep 2018', 'Status_History__c': 'a132P000000ArXGQA0'}, 'change': None}]",Sep 2018,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZFUUA2'}, 'Id': 'a0P2P000006hZFUUA2', 'Event_Date__c': '2019-10-15', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000B2UdQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> that the application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) be declined. The Subcommittee considered that there is no\xa0evidence for a benefit from vaccination with PPV23 in addition to PCV13 in untreated CLL/SLL.\xa0</p>', 'fs': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> that the application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) be declined. The Subcommittee considered that there is no\xa0evidence for a benefit from vaccination with PPV23 in addition to PCV13 in untreated CLL/SLL.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<p style=""text-align: justify;"">The Subcommittee noted that Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPV23) are currently listed in the Pharmaceutical Schedule for children up to the age of 59 months as well as for high risk individuals. PCV13 is funded for pre- or post-haematopoietic stem cell transplant (HSCT) or chemotherapy, but PPV23 is only currently funded post-HSCT or chemotherapy. The Subcommittee considered that current funding criteria for PCV13 would mean that all CLL/SLL patients would be eligible for PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a randomised controlled trial by the Swedish CLL Group (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29748028"" target=""_blank"">Svensson et al. Vaccine 2018;36:3701-7</a>). The Subcommittee noted that the study was intended to determine if patients with untreated CLL would generate a greater immune response from vaccination with PCV13 compared with PPV23, for most serotypes common to both vaccines. The trial demonstrated a better immune response to PCV13 than PPV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination. The authors proposed that PCV13 should be administered as early as possible during the course of the disease, with PPV23 eight weeks later.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review of infectious complications in patients with CLL (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/19858055"" target=""_blank"">Morrison VA. Clin Lymphoma Myeloma 2009;9:365-70</a>). The review noted that CLL/SLL patients have an elevated risk of pneumococcal disease. A number of immunisations have been examined in patients with CLL but they have shown suboptimal responses because of impaired antibody production and defects in antigen presentation. The review noted that conjugated vaccines would be more likely to give better responses than polysaccharide vaccines.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the British Committee for Standards in Haematology (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23057493"" target=""_blank"">Oscier et al. Br. J. Haematol 2012;159:541-64</a>). The Subcommittee noted that the guideline discusses immunisation and recommendations for immunisations for people with CLL. It notes that there are no randomised studies showing that vaccination of any type alters infection rates of outcomes from acquired infections in CLL. The guidelines note that some patients respond particularly if vaccinated early in the disease and if conjugate vaccines for <i>S, pneumoniae</i> are used (PCV13).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review article addressing the pathogenesis of infections due to CLL or therapy-related immunosuppression (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29160119"" target=""_blank"">Tadmor et al. Expert Rev Hematol. 2018;11:57-70</a>). The Subcommittee noted that the majority of patients with CLL suffer from infections during their disease and these account for approximately 60% of deaths in CLL. Patients are predisposed to infection both as a consequence of CLL and as a result of therapy. The review noted that in the absence of agreed international guidelines, several national bodies have recommended infection prophylaxis in specific circumstances. The Subcommittee noted that this would include offering up to three doses of PPV23 for patients who have already received one dose of PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the European Society for Medical Oncology (ESMO) Guidelines Committee (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26314781"" target=""_blank"">Eichhorst et al. Ann Onc 2015;26 Suppl 5:v78-84</a>). The Subcommittee noted that the guideline considers that infections are a common complication in CLL patients following treatment with immunosuppressive agents. The guideline recommended pneumococcal vaccination in early-stage CLL, but did not specify the vaccine type or pneumococcal serotypes covered.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered that the evidence for benefit from vaccination with PCV13 followed by PPV23 was of poor quality and low strength, consisting of small observational studies and international guideline recommendations. The Subcommittee considered that the above Svensson et al. 2018 trial demonstrated a good immune response to PCV13, but did not provide evidence of additional benefit for subsequent vaccination with PPV23. The Subcommittee considered that there is a theoretical benefit to broadening immune response to more serotypes with PPV23, but this is not supported by the evidence at this time. The Subcommittee considered that the evidence did not support amending the eligibility criteria for PPV23 with respect to immunosuppression to be aligned with those for PCV13.\xa0</p>', 'fs': '<p style=""text-align: justify;"">The Subcommittee noted that Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPV23) are currently listed in the Pharmaceutical Schedule for children up to the age of 59 months as well as for high risk individuals. PCV13 is funded for pre- or post-haematopoietic stem cell transplant (HSCT) or chemotherapy, but PPV23 is only currently funded post-HSCT or chemotherapy. The Subcommittee considered that current funding criteria for PCV13 would mean that all CLL/SLL patients would be eligible for PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a randomised controlled trial by the Swedish CLL Group (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29748028"" target=""_blank"">Svensson et al. Vaccine 2018;36:3701-7</a>). The Subcommittee noted that the study was intended to determine if patients with untreated CLL would generate a greater immune response from vaccination with PCV13 compared with PPV23, for most serotypes common to both vaccines. The trial demonstrated a better immune response to PCV13 than PPV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination. The authors proposed that PCV13 should be administered as early as possible during the course of the disease, with PPV23 eight weeks later.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review of infectious complications in patients with CLL (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/19858055"" target=""_blank"">Morrison VA. Clin Lymphoma Myeloma 2009;9:365-70</a>). The review noted that CLL/SLL patients have an elevated risk of pneumococcal disease. A number of immunisations have been examined in patients with CLL but they have shown suboptimal responses because of impaired antibody production and defects in antigen presentation. The review noted that conjugated vaccines would be more likely to give better responses than polysaccharide vaccines.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the British Committee for Standards in Haematology (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23057493"" target=""_blank"">Oscier et al. Br. J. Haematol 2012;159:541-64</a>). The Subcommittee noted that the guideline discusses immunisation and recommendations for immunisations for people with CLL. It notes that there are no randomised studies showing that vaccination of any type alters infection rates of outcomes from acquired infections in CLL. The guidelines note that some patients respond particularly if vaccinated early in the disease and if conjugate vaccines for <i>S, pneumoniae</i> are used (PCV13).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review article addressing the pathogenesis of infections due to CLL or therapy-related immunosuppression (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29160119"" target=""_blank"">Tadmor et al. Expert Rev Hematol. 2018;11:57-70</a>). The Subcommittee noted that the majority of patients with CLL suffer from infections during their disease and these account for approximately 60% of deaths in CLL. Patients are predisposed to infection both as a consequence of CLL and as a result of therapy. The review noted that in the absence of agreed international guidelines, several national bodies have recommended infection prophylaxis in specific circumstances. The Subcommittee noted that this would include offering up to three doses of PPV23 for patients who have already received one dose of PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the European Society for Medical Oncology (ESMO) Guidelines Committee (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26314781"" target=""_blank"">Eichhorst et al. Ann Onc 2015;26 Suppl 5:v78-84</a>). The Subcommittee noted that the guideline considers that infections are a common complication in CLL patients following treatment with immunosuppressive agents. The guideline recommended pneumococcal vaccination in early-stage CLL, but did not specify the vaccine type or pneumococcal serotypes covered.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered that the evidence for benefit from vaccination with PCV13 followed by PPV23 was of poor quality and low strength, consisting of small observational studies and international guideline recommendations. The Subcommittee considered that the above Svensson et al. 2018 trial demonstrated a good immune response to PCV13, but did not provide evidence of additional benefit for subsequent vaccination with PPV23. The Subcommittee considered that there is a theoretical benefit to broadening immune response to more serotypes with PPV23, but this is not supported by the evidence at this time. The Subcommittee considered that the evidence did not support amending the eligibility criteria for PPV23 with respect to immunosuppression to be aligned with those for PCV13.\xa0</p>', 'change': None}, 'Published_Application': {'s': '<p style=""text-align: justify;"">The Subcommittee considered a clinician funding application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).\xa0</p>', 'fs': '<p style=""text-align: justify;"">The Subcommittee considered a clinician funding application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application. </span></p>', 'fs': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application. </span></p>', 'change': None}, 'Outcome': {'s': 'Decline', 'fs': 'Decline', 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-record-2019-10.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-record-2019-10.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Mar 2020', 'fs': 'Mar 2020', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 15 October 2019.', 'fs': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 15 October 2019.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZFVUA2'}, 'Id': 'a0P2P000006hZFVUA2', 'Event_Date__c': '2020-03-16', 'Event_Description__c': 'Clinical advice received from Immunisation Subcommittee at meeting Tuesday 15 October 2019.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p><a href=""https://pharmac.govt.nz/assets/ptac-immunisation-subcommittee-record-2019-10.pdf"" target=""_blank"">Immunisation Subcommittee minutes</a></p>', 'Outcome__c': 'Decline', 'Formatted_Date__c': 'Mar 2020', 'Published_Recommendation__c': '<p style=""text-align: justify;"">The Subcommittee <b>recommended</b> that the application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) be declined. The Subcommittee considered that there is no\xa0evidence for a benefit from vaccination with PPV23 in addition to PCV13 in untreated CLL/SLL.\xa0</p>', 'Published_Application__c': '<p style=""text-align: justify;"">The Subcommittee considered a clinician funding application to widen access to PPV23 vaccine for patients with untreated chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL).\xa0</p>', 'Published_Discussion__c': '<p style=""text-align: justify;"">The Subcommittee noted that Pneumococcal Conjugate Vaccine (PCV13) and Pneumococcal Polysaccharide Vaccine (PPV23) are currently listed in the Pharmaceutical Schedule for children up to the age of 59 months as well as for high risk individuals. PCV13 is funded for pre- or post-haematopoietic stem cell transplant (HSCT) or chemotherapy, but PPV23 is only currently funded post-HSCT or chemotherapy. The Subcommittee considered that current funding criteria for PCV13 would mean that all CLL/SLL patients would be eligible for PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a randomised controlled trial by the Swedish CLL Group (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29748028"" target=""_blank"">Svensson et al. Vaccine 2018;36:3701-7</a>). The Subcommittee noted that the study was intended to determine if patients with untreated CLL would generate a greater immune response from vaccination with PCV13 compared with PPV23, for most serotypes common to both vaccines. The trial demonstrated a better immune response to PCV13 than PPV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination. The authors proposed that PCV13 should be administered as early as possible during the course of the disease, with PPV23 eight weeks later.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review of infectious complications in patients with CLL (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/19858055"" target=""_blank"">Morrison VA. Clin Lymphoma Myeloma 2009;9:365-70</a>). The review noted that CLL/SLL patients have an elevated risk of pneumococcal disease. A number of immunisations have been examined in patients with CLL but they have shown suboptimal responses because of impaired antibody production and defects in antigen presentation. The review noted that conjugated vaccines would be more likely to give better responses than polysaccharide vaccines.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the British Committee for Standards in Haematology (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/23057493"" target=""_blank"">Oscier et al. Br. J. Haematol 2012;159:541-64</a>). The Subcommittee noted that the guideline discusses immunisation and recommendations for immunisations for people with CLL. It notes that there are no randomised studies showing that vaccination of any type alters infection rates of outcomes from acquired infections in CLL. The guidelines note that some patients respond particularly if vaccinated early in the disease and if conjugate vaccines for <i>S, pneumoniae</i> are used (PCV13).</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a review article addressing the pathogenesis of infections due to CLL or therapy-related immunosuppression (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/29160119"" target=""_blank"">Tadmor et al. Expert Rev Hematol. 2018;11:57-70</a>). The Subcommittee noted that the majority of patients with CLL suffer from infections during their disease and these account for approximately 60% of deaths in CLL. Patients are predisposed to infection both as a consequence of CLL and as a result of therapy. The review noted that in the absence of agreed international guidelines, several national bodies have recommended infection prophylaxis in specific circumstances. The Subcommittee noted that this would include offering up to three doses of PPV23 for patients who have already received one dose of PCV13.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered a clinical practice guideline from the European Society for Medical Oncology (ESMO) Guidelines Committee (<a href=""https://www.ncbi.nlm.nih.gov/pubmed/26314781"" target=""_blank"">Eichhorst et al. Ann Onc 2015;26 Suppl 5:v78-84</a>). The Subcommittee noted that the guideline considers that infections are a common complication in CLL patients following treatment with immunosuppressive agents. The guideline recommended pneumococcal vaccination in early-stage CLL, but did not specify the vaccine type or pneumococcal serotypes covered.</p><p style=""text-align: justify;""><br></p><p style=""text-align: justify;"">The Subcommittee considered that the evidence for benefit from vaccination with PCV13 followed by PPV23 was of poor quality and low strength, consisting of small observational studies and international guideline recommendations. The Subcommittee considered that the above Svensson et al. 2018 trial demonstrated a good immune response to PCV13, but did not provide evidence of additional benefit for subsequent vaccination with PPV23. The Subcommittee considered that there is a theoretical benefit to broadening immune response to more serotypes with PPV23, but this is not supported by the evidence at this time. The Subcommittee considered that the evidence did not support amending the eligibility criteria for PPV23 with respect to immunosuppression to be aligned with those for PCV13.\xa0</p>', 'PTAC_Comments__c': '<p><span style=""font-size: 13.3333px; font-family: Arial, sans-serif; color: rgb(62, 62, 60);"">PTAC noted and agreed with the Subcommittee’s recorded considerations and recommendations regarding\xa0this application. </span></p>', 'Status_History__c': 'a132P000000BaC9QAK'}, 'change': None}]",Oct 2019,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZFWUA2'}, 'Id': 'a0P2P000006hZFWUA2', 'Event_Date__c': '2021-05-03', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000CoWLQA0'}, 'change': None}]",May 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2021', 'fs': 'May 2021', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZLKUA2'}, 'Id': 'a0P2P000006hZLKUA2', 'Event_Date__c': '2021-05-27', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'May 2021', 'Status_History__c': 'a132P000000CsgZQAS'}, 'change': None}]",May 2021,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Jun 2021', 'fs': 'Jun 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZLLUA2'}, 'Id': 'a0P2P000006hZLLUA2', 'Event_Date__c': '2021-06-29', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""background-color: rgb(255, 255, 255);"">https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2021-06-29-proposal-to-decline-inactive-funding-applications</a></p>', 'Formatted_Date__c': 'Jun 2021', 'Status_History__c': 'a132P000000CxvgQAC'}, 'change': None}]",Jun 2021,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Aug 2021', 'fs': 'Aug 2021', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZLMUA2'}, 'Id': 'a0P2P000006hZLMUA2', 'Event_Date__c': '2021-08-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Aug 2021', 'Status_History__c': 'a132P000000D3xXQAS'}, 'change': None}]",Aug 2021,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Feb 2022', 'fs': 'Feb 2022', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0P2P000006hZLNUA2'}, 'Id': 'a0P2P000006hZLNUA2', 'Event_Date__c': '2022-02-04', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/decision-2022-03-08-inactive-declines/"" target=""_blank"">Notification letter</a></p>', 'Formatted_Date__c': 'Feb 2022', 'Status_History__c': 'a132P000000DaqxQAC'}, 'change': None}]",Feb 2022,False,True
